PL2389352T3 - Inhibitory arginazy oraz sposoby zastosowania - Google Patents

Inhibitory arginazy oraz sposoby zastosowania

Info

Publication number
PL2389352T3
PL2389352T3 PL10734002T PL10734002T PL2389352T3 PL 2389352 T3 PL2389352 T3 PL 2389352T3 PL 10734002 T PL10734002 T PL 10734002T PL 10734002 T PL10734002 T PL 10734002T PL 2389352 T3 PL2389352 T3 PL 2389352T3
Authority
PL
Poland
Prior art keywords
methods
arginase inhibitors
arginase
inhibitors
Prior art date
Application number
PL10734002T
Other languages
English (en)
Inventor
David W Christianson
Bruce Edward Tomczuk
Richard Scott Pottorf
Andrew Vargha Colasanti
Gary Lee Olson
Original Assignee
Univ Pennsylvania
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Astrazeneca Uk Ltd filed Critical Univ Pennsylvania
Publication of PL2389352T3 publication Critical patent/PL2389352T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
PL10734002T 2009-01-26 2010-01-26 Inhibitory arginazy oraz sposoby zastosowania PL2389352T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14727009P 2009-01-26 2009-01-26
EP10734002.8A EP2389352B1 (en) 2009-01-26 2010-01-26 Arginase inhibitors and methods of use
PCT/US2010/022090 WO2010085797A2 (en) 2009-01-26 2010-01-26 Arginase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
PL2389352T3 true PL2389352T3 (pl) 2019-10-31

Family

ID=42354317

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10734002T PL2389352T3 (pl) 2009-01-26 2010-01-26 Inhibitory arginazy oraz sposoby zastosowania

Country Status (16)

Country Link
US (4) US20100189644A1 (pl)
EP (1) EP2389352B1 (pl)
JP (2) JP2012515799A (pl)
CA (1) CA2749853C (pl)
CY (1) CY1121815T1 (pl)
DK (1) DK2389352T3 (pl)
ES (1) ES2729474T3 (pl)
HR (1) HRP20191433T1 (pl)
HU (1) HUE046932T2 (pl)
LT (1) LT2389352T (pl)
PL (1) PL2389352T3 (pl)
PT (1) PT2389352T (pl)
RS (1) RS58965B1 (pl)
SI (1) SI2389352T1 (pl)
TR (1) TR201910726T4 (pl)
WO (1) WO2010085797A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796867C (en) * 2010-04-22 2019-04-09 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
SI2632927T1 (sl) * 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
RU2019121905A (ru) * 2010-12-31 2019-09-03 Астразенека Юкей Лимитед Ингибиторы аргиназы и способы их применения
WO2013056163A1 (en) * 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
CA2852685C (en) * 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
US10299377B2 (en) 2011-12-22 2019-05-21 Fujifilm Corporation Conductive sheet and touch panel
US9200011B2 (en) 2012-04-18 2015-12-01 Mars, Incorporated Ring constrained analogs as arginase inhibitors
ES2903151T3 (es) * 2012-12-04 2022-03-31 Aribio Inc Composición que comprende inhibidor de fosfodiesterasa tipo 5 para inhibir la apoptosis de células nerviosas
CA2944903A1 (en) 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US10143699B2 (en) 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108601767A (zh) * 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
CR20210389A (es) 2015-10-30 2021-09-16 Calithera Biosciences Inc Composiciones y métodos para inhibir la actividad arginasa (divisional 2018-0282)
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
JP6581308B2 (ja) * 2016-10-17 2019-09-25 一般社団法人 金沢大整形 癌治療剤
JP2020502259A (ja) 2016-11-08 2020-01-23 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ阻害剤併用療法
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
JP2020519583A (ja) 2017-05-12 2020-07-02 カリセラ バイオサイエンシズ，インコーポレイテッド （３ｒ，４ｓ）−３−アセトアミド−４−アリル−ｎ−（ｔｅｒｔ−ブチル）ピロリジン−３−カルボキサミドの製造方法
CA3094939A1 (en) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
RU2695333C1 (ru) * 2018-09-24 2019-07-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемически-реперфузионных повреждений почек ингибитором аргиназы II в эксперименте
RU2696580C1 (ru) * 2018-09-25 2019-08-05 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики нарушений функций почек ингибитором аргиназы II в эксперименте
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477391A (en) 1981-08-14 1984-10-16 Collins James F Amino acid isomers, their production and their medicinal use
AU9797998A (en) * 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
US6784178B2 (en) * 2000-04-12 2004-08-31 Cornell Research Foundation, Inc. Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
US20050203082A1 (en) * 2003-08-13 2005-09-15 Hsu Chung Y. Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
EP2083812B1 (en) * 2006-11-21 2017-04-05 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis

Also Published As

Publication number Publication date
CA2749853A1 (en) 2010-07-29
HUE046932T2 (hu) 2020-04-28
TR201910726T4 (tr) 2019-08-21
US20190127395A1 (en) 2019-05-02
LT2389352T (lt) 2019-06-10
CA2749853C (en) 2018-08-21
HRP20191433T1 (hr) 2019-11-15
PT2389352T (pt) 2019-08-23
WO2010085797A3 (en) 2010-11-04
ES2729474T3 (es) 2019-11-04
US20160194340A1 (en) 2016-07-07
US10118936B2 (en) 2018-11-06
SI2389352T1 (sl) 2019-08-30
US20200223871A1 (en) 2020-07-16
JP2012515799A (ja) 2012-07-12
EP2389352A2 (en) 2011-11-30
WO2010085797A2 (en) 2010-07-29
JP6177832B2 (ja) 2017-08-09
EP2389352A4 (en) 2013-02-20
CY1121815T1 (el) 2020-07-31
RS58965B1 (sr) 2019-08-30
EP2389352B1 (en) 2019-05-08
US20100189644A1 (en) 2010-07-29
AU2010206535A1 (en) 2011-07-28
JP2015205891A (ja) 2015-11-19
DK2389352T3 (da) 2019-07-29

Similar Documents

Publication Publication Date Title
HUE046932T2 (hu) Argináz inhibitorok és felhasználási eljárások
HK1213769A1 (zh) 精氨酸酶抑制劑及其使用方法
IL240771A0 (en) Benzoxazole kinase inhibitors and methods of use
EP2424857A4 (en) DOUBLE ACTION INHIBITORS AND METHODS OF USE
EP2379561A4 (en) MLK INHIBITORS AND METHODS OF USE
HK1160119A1 (en) Kinase inhibitors and methods of use
IL224389A (en) Demetylase inhibitors of arsylcyclopropylamine-based lsd1 and their medical use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
IL214226A (en) Inhibitors of beta-secretase and various related aspects thereof
HK1149933A1 (en) Diazacarbazoles and methods of use
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
IL209548A0 (en) Diazacarbazoles and methods of use
EP2344204A4 (en) TELOMERASE INHIBITOR AND METHOD OF USE THEREOF
EP2536709A4 (en) PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE
EP2393787A4 (en) CADHERINE 11 INHIBITORS AND METHOD FOR THEIR USE
ZA201301795B (en) Inhibitors of notum pectinacetylesterase and methods of their use
EP2242367A4 (en) REL INHIBITORS AND METHODS OF USE
ZA201106083B (en) Inhibitors of viral integrase and methods of use
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法